Lilly’s Intended Successor To Zyprexa Faces Uncertain Future After Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Failure to perform better than placebo in the first of two pivotal Phase III trials diminishes chances of success for pomaglumetad methionil, a metabotropic glutamate 2/3 receptor agonist that Lilly hoped to position as a successor to its patent-expired schizophrenia therapy Zyprexa.
You may also be interested in...
No Big Surprises From Lilly: Management Sticks To Its Guns On Strategy
With the loss of Zyprexa just months away, Eli Lilly management sought to reassure investors its strategy of focusing on its internal pipeline and core growth areas will pay off post-2014.
Lilly’s mGlu2/3 Agonist Fails In Phase II For Schizophrenia – But So Does Zyprexa
Lilly vows to do another Phase II in effort to replicate an earlier study that showed efficacy for the novel schizophrenia drug over placebo.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.